DEODHAR, A., R. BLANCO, Eva DOKOUPILOVÁ, M. VAN DE SANDE, S. HALL, A. WIKSTEN, B. O. PORTER, H. O. RICHARDS, S. HAEMMERLE and J. BRAUNS. SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY. 2020. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{1746229, author = {Deodhar, A. and Blanco, R. and Dokoupilová, Eva and van de Sande, M. and Hall, S. and Wiksten, A. and Porter, B. O. and Richards, H. O. and Haemmerle, S. and Brauns, J.}, keywords = {secukinumab; signs; symptoms; non radiographic axial; spondyloarthritis; prevent study}, language = {eng}, title = {SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY}, url = {https://ard.bmj.com/content/79/Suppl_1/69}, year = {2020} }
TY - CONF ID - 1746229 AU - Deodhar, A. - Blanco, R. - Dokoupilová, Eva - van de Sande, M. - Hall, S. - Wiksten, A. - Porter, B. O. - Richards, H. O. - Haemmerle, S. - Brauns, J. PY - 2020 TI - SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY KW - secukinumab KW - signs KW - symptoms KW - non radiographic axial KW - spondyloarthritis KW - prevent study UR - https://ard.bmj.com/content/79/Suppl_1/69 N2 - Our findings indicate that secukinumab 150 mg provides significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports ER -
DEODHAR, A., R. BLANCO, Eva DOKOUPILOVÁ, M. VAN DE SANDE, S. HALL, A. WIKSTEN, B. O. PORTER, H. O. RICHARDS, S. HAEMMERLE and J. BRAUNS. \textit{SECUKINUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHIUTIS: 16-WEEK RESULTS FROM THE PHASE-III PREVENT STUDY}. 2020.
|